MAIbe and LenioBio Partner to Advance Antibody Discovery

In Düsseldorf, Germany, a new collaboration between mAIbe and LenioBio is set to transform the discovery and validation of next-generation monoclonal antibodies. This strategic partnership combines mAIbe's AI-driven platform with LenioBio's cell-free expression technology, enhancing the antibody design-build-test cycle.

LenioBio's scalable system allows for the rapid production of complex antibodies, providing crucial experimental data for mAIbe's AI models. Together, the companies aim to accelerate functional testing, increase validation efficiency, and improve the iterative process between computational predictions and experimental outcomes.

This collaboration marks a significant advancement in speed, flexibility, and data-driven innovation for therapeutic antibody discovery, bridging the lab-in-loop gap.